This article is more than 5 years old. Information may no longer be current.
Dextenza launches in US
Click Here to Manage Email Alerts
Ocular Therapeutix has commercially launched Dextenza in the United States for the treatment of ocular inflammation and pain after ophthalmic surgery, according to a press release.
The first FDA-approved intracanalicular insert, Dextenza (dexamethasone ophthalmic insert 0.4 mg) was approved in November 2018 for ocular pain and in June for ocular inflammation.
The launch is supported by the activation of a CMS C-code, C9048, which allows reimbursement for Dextenza until CMS approves a J-code.
“With reimbursement solidified through a unique C-code, the addition of inflammation to our label and our direct, highly experienced commercial team in place, we believe we are well-prepared for the launch of Dextenza,” Ocular Therapeutix President and CEO Antony Mattessich said in the release. “Dextenza represents a novel new treatment option that we believe offers significant value to both patients and physicians, and we are excited for its potential in the market.”